arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Arcturus Therapeutics Holdings Inc.

ARCT
$13.28 ▼ -1.13 (-7.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcturus Therapeutics Holdings Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $377.5M
Dividend Yield —
Revenue Growth -89.5% ↗
Op. Margin None
ROIC -14.9% ↘
FCF / Share $-0.70 ↘
Trailing P/E —
Price / Book 2.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.96M
↓ -89.5% —
Net Income Profit after all expenses
$-26.96M
↓ -193.7% —
Operating Margin Operating profit as % of sales
-435.1%
↓ -351.9% 2th
FCF / Share Free cash flow per share
$-0.70
↓ -2.4% —
Long-Term Debt Long-term obligations
$15.00M
↓ -25.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns ↑
23
Cash Quality ↑
70

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters